KRAS and neoplasm: The nanoparticles were tested in transgenic mouse models of KRAS-mutant pancreatic cancer, confirming specific accumulation at tumor sites, delivery of micro-RNA (miRNA) 125b, and conversion of macrophages from M2 (pro-tumor) to M1 (anti-tumor), compared with nanoparticles carrying a scrambled miRNA.